• 1
    Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026.
  • 2
    Mohd Hanafiah K, Groeger J, Flaxman A, Wiersma T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
  • 3
    Ly KN, Xing J, Klevens M, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-278.
  • 4
    Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al.; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
  • 5
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
  • 6
    Laetz T, Siberman G. Reimbursement policies constrain the practice of oncology. JAMA 1991;266:2996-2991
  • 7
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med;364:1195-1206.
  • 8
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med;364:2405-2416.
  • 9
    De Clerca E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol 2009;19:287-299.
  • 10
    Collier AC, Coombs RD, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-1018.
  • 11
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
  • 12
    FDA. Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices. Department of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Policy. January 2009. Available at: Accessed on September 2, 2013.
  • 13
    Cohen A, Wilson A, Faden L. Off-label use reimbursement. Food Drug Law J 2009;64:391-403.
  • 14
    Lawitz E, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Jacobson I, et al. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. Presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March 3-6, 2013